HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma

Autor: Antonio Cigliano, Isabella Gigante, Marina Serra, Gianpaolo Vidili, Maria M. Simile, Sara Steinmann, Francesco Urigo, Eleonora Cossu, Giovanni M. Pes, Maria P. Dore, Silvia Ribback, Egle P. Milia, Elena Pizzuto, Serena Mancarella, Li Che, Rosa M. Pascale, Gianluigi Giannelli, Matthias Evert, Xin Chen, Diego F. Calvisi
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-17 (2024)
Druh dokumentu: article
ISSN: 1756-9966
DOI: 10.1186/s13046-024-03177-7
Popis: Abstract Background Intrahepatic cholangiocarcinoma (iCCA) is a lethal primary liver tumor characterized by clinical aggressiveness, poor prognosis, and scarce therapeutic possibilities. Therefore, new treatments are urgently needed to render this disease curable. Since cumulating evidence supports the oncogenic properties of the Heat Shock Factor 1 (HSF1) transcription factor in various cancer types, we investigated its pathogenetic and therapeutic relevance in iCCA. Methods Levels of HSF1 were evaluated in a vast collection of iCCA specimens. The effects of HSF1 inactivation on iCCA development in vivo were investigated using three established oncogene-driven iCCA mouse models. In addition, the impact of HSF1 suppression on tumor cells and tumor stroma was assessed in iCCA cell lines, human iCCA cancer-associated fibroblasts (hCAFs), and patient-derived organoids. Results Human preinvasive, invasive, and metastatic iCCAs displayed widespread HSF1 upregulation, which was associated with a dismal prognosis of the patients. In addition, hydrodynamic injection of a dominant-negative form of HSF1 (HSF1dn), which suppresses HSF1 activity, significantly delayed cholangiocarcinogenesis in AKT/NICD, AKT/YAP, and AKT/TAZ mice. In iCCA cell lines, iCCA hCAFs, and patient-derived organoids, administration of the HSF1 inhibitor KRIBB-11 significantly reduced proliferation and induced apoptosis. Cell death was profoundly augmented by concomitant administration of the Bcl-xL/Bcl2/Bcl-w inhibitor ABT-263. Furthermore, KRIBB-11 reduced mitochondrial bioenergetics and glycolysis of iCCA cells. Conclusions The present data underscore the critical pathogenetic, prognostic, and therapeutic role of HSF1 in cholangiocarcinogenesis.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje